Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study
Tarih
2014Yazar
van Laar, Teus
Burn, David
Micheli, Federico
Storch, Alexander
Emre, Murat
Poewe, Werner
De Deyn, Peter Paul
Barone, Paolo
Kulisevsky, Jaime
Pourcher, Emmanuelle
Strohmaier, Christine
Tenenbaum, Nadia
Callegari, Francesca
Pahwa, Rajesh
Durif, Frank
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.
Koleksiyonlar
- Makale [92796]